Levodopa in Parkinson’s Disease: Current Status and Future DevelopmentsNicola Tambasco(Azienda Ospedaliera di Perugia), Paolo Calabresi(Università Cattolica del Sacro Cuore)Current NeuropharmacologyOctober 13, 201710.2174/1570159x15666170510143821Cited by 276SaveCiteExport RISWatch citationsRelated PapersAlpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction|Cell Death and Disease|2023|710Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity.|PubMed|2000|347Dopamine and cAMP-Regulated Phosphoprotein 32 kDa Controls Both Striatal Long-Term Depression and Long-Term Potentiation, Opposing Forms of Synaptic Plasticity|Journal of Neuroscience|2000|331